Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | TP53 Y220C |
| Gene Variant Detail | |
| Relevant Treatment Approaches | p53 Activator p53 Gene Therapy |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07060989 | Phase Ib/II | NTS071 | A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (NTS071) | Not yet recruiting | USA | 1 |
| NCT04585750 | Phase Ib/II | PC14586 + Pembrolizumab PC14586 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
| NCT06386146 | Phase Ib/II | JAB-30355 | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Recruiting | USA | 1 |
| NCT06616636 | Phase I | Azacitidine + PC14586 Azacitidine + PC14586 + Venetoclax | A Phase Ib Study of Rezatapopt in Combination with Azacitidine or Azacitidine and Venetoclax in Patients with TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | Recruiting | USA | 0 |